

VAXIL BIO LTD

**CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Unaudited)
(Expressed in Thousands of Canadian Dollars)**

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020

INDEX

	<u>Page</u>
Condensed Consolidated Interim Statements of Financial Position	3
Condensed Consolidated Interim Statements of Loss of Comprehensive and Loss	4
Condensed Consolidated Interim Statements of Cash Flows	5
Consolidated Statements of Changes in Equity (Deficiency)	6
Notes to the Condensed Consolidated Interim Financial Statements	7 - 15

**NOTICE OF NO AUDITOR REVIEW OF THE
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

In accordance with National Instrument 51-102 - *Continuous Disclosure Obligations*, of the Canadian Securities Administrators, the Company (as defined herein) discloses that its auditors have not reviewed the unaudited condensed interim consolidated financial statements.

The accompanying unaudited condensed interim consolidated financial statements of Vaxil Bio (“Vaxil”, the “Company”) for the three and nine month periods ended September 30, 2020 have been prepared by and are the responsibility of the Company’s management and have not been reviewed by the Company’s auditors.

VAXIL BIO LTD**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION**

(Unaudited)

(Expressed in Thousands of Canadian Dollars, except per share data)

	Note	September 30 2020	December 31 2019
		<u>Unaudited</u>	<u>Audited</u>
ASSETS			
Current assets			
Cash		\$ 778	\$ 83
Amounts receivable and prepaid expenses		49	27
Total current assets		827	110
Equipment, net		22	25
Rights of use assets		27	70
Total Assets		\$ 876	\$ 205
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities			
Accounts payable		499	618
Other accounts payable and accrued liabilities		41	96
Unsecured Loans- related parties	4,5	101	-
Short term portion of lease liability		35	63
Total current liabilities		676	777
Long term liabilities			
Long term lease liabilities		-	11
Total liabilities		676	788
Shareholders' equity (deficit)			
Share capital	6	13,056	11,234
Warrant reserve	6	444	816
Contributed surplus	6	3,748	3,620
Foreign currency transaction reserve		(90)	(32)
Accumulated deficit		(16,958)	(16,221)
Total shareholders' equity (deficit)		200	(583)
Total liabilities and shareholders' equity (deficit)		\$ 876	\$ 205

Nature and continuance of operations (Note 1)

Commitments (Note 9)

Subsequent Events (Note 11)

Approved and authorized by the Board on November 26, 2020:

"Gadi Levin"

Gadi Levin

Director

"David Goren"

David Goren

Director

The accompanying condensed notes are an integral part of these condensed consolidated interim financial statements.

VAXIL BIO LTD
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(Unaudited)
(Expressed in Thousands of Canadian Dollars, except per share data)

	Note	Three months ended		Nine Month ended	
		September 30		September 30	
		2020	2019	2020	2019
		Unaudited		Unaudited	
Expenses:					
Research and development costs	7	\$ 133	\$ 113	385	\$ 409
General and administration costs	8	100	63	275	133
Share based compensation	6	73	31	108	118
Total Expenses		306	207	768	660
Operating Loss		(306)	(207)	(768)	(660)
Financial Expenses	3	7	-	15	2
Net loss for the period		(313)	(207)	(783)	(662)
Other Comprehensive Loss					
Foreign currency translation adjustment		(22)	(4)	(58)	(9)
Net loss and comprehensive loss for the period		\$ (335)	\$ (211)	\$ (841)	\$ (671)
Basic and Fully Diluted Loss Per Share		\$ (0.01)	\$ (0.00)	\$ (0.01)	\$ (0.01)
Weighted Average Number Of Shares Outstanding		103,771,984	88,929,447	99,410,655	88,929,447

The accompanying condensed notes are an integral part of these condensed consolidated interim financial statements.

VAXIL BIO LTD
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
(Unaudited)
(Expressed in Thousands of Canadian Dollars, except per share data)

	Nine Month ended	
	September 30	
	2020	2019
	Unaudited	
Cash flows from operating activities		
Net loss for the period	\$ (783)	\$ (662)
Items not affecting cash:		
Depreciation	46	37
Interest on loans	15	1
Share-based compensation	108	118
Changes in non-cash working capital:		
Amounts receivable and prepaid expenses	(22)	24
Accounts payable	(119)	54
Other accounts payable and accrued liabilities	(55)	(102)
	(810)	(530)
Cash flows from financing activities		
Loan repayment	-	(25)
Lease repayment	(46)	-
Proceeds from unsecured convertible loans	36	-
Proceeds from unsecured loans	95	-
Proceeds from exercise of warrants	1,478	-
	1,563	(25)
Increase (decrease) in cash	753	(555)
Effect of changes in foreign exchange rates	(58)	(10)
Cash, beginning of period	83	753
Cash, end of period	\$ 778	\$ 188

The accompanying condensed notes are an integral part of these condensed consolidated interim financial statements.

VAXIL BIO LTD
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)
(Unaudited)
(Expressed in Thousands of Canadian Dollars, except per share data)

	Ordinary share capital		Warrant reserve	Contributed surplus	Foreign currency transaction reserve	Accumulated deficit	Total Equity (Capital Deficiency)
	Number of shares	Amount					
Balance - January 1, 2019	88,929,447	\$ 11,234	\$ 1,910	\$ 2,425	\$ (26)	\$ (15,108)	\$ 435
Expiration of warrants	-	-	(869)	869	-	-	-
Cancellation of options (Note 4 (c))	-	-	-	(37)	-	37	-
Share based compensation	-	-	-	118	-	-	118
Net comprehensive loss for the period	-	-	-	-	(9)	(662)	(671)
Balance - September 30, 2019	88,929,447	\$ 11,234	\$ 1,041	\$ 3,375	\$ (35)	\$ (15,733)	\$ (118)
Expiration of warrants	-	-	(225)	225.00	-	-	-
Cancellation of options	-	-	-	(4)	-	41	37
Share based compensation	-	-	-	24	-	-	24
Net comprehensive loss for the period	-	-	-	-	3	(492)	(489)
Balance - December 31, 2019	88,929,447	11,234	\$ 816	\$ 3,620	(32)	(16,221)	(583)
Exercise of warrants (Note 6(b))	14,780,000	1,784	(306)	-	-	-	1,478
Cancellation of options (Note 6(d)(i)(I))	-	-	-	(46)	-	46	-
Expiration of warrants (Note 6(e)(i)(I))	-	-	(66)	66	-	-	-
Issuance of shares on conversion on convertible loan (Note 6(c))	740,086	38	-	-	-	-	38
Share based compensation (Note 6(d)(ii))	-	-	-	108	-	-	108
Net comprehensive loss for the period	-	-	-	-	(58)	(783)	(841)
Balance - September 2020	104,449,533	\$ 13,056	\$ 444	\$ 3,748	\$ (90)	\$ (16,958)	\$ 200

The accompanying condensed notes are an integral part of these condensed consolidated interim financial statements.

1. **NATURE AND CONTINUANCE OF OPERATIONS AND GOING CONCERN**

Vaxil Bio Ltd (“Vaxil” or the “Company”) was incorporated under the Business Corporations Act (BC) on July 26, 2006 and is listed on the TSX Venture Exchange (“TSX-V”). Vaxil is an Israeli biotechnology company that is focused on a novel drug discovery and development platform based on Signal Peptides (“SPs”) which the company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin™, successfully completed a Phase 1/2a clinical trial in multiple myeloma and received orphan drug status from the FDA and EMA. The Company also announced a COVID-19 vaccine candidate and is developing a tuberculosis vaccine / treatment that has demonstrated promising preliminary results at a top US academic and research institution. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.

The Company trades on the TSX-V under the symbol “VXL.V”. The Company's head office is located at 3400 One First Canadian Place, ON, M5X 1A4, Toronto, Ontario.

The accompanying consolidated financial statements have been prepared on the basis of a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business for the foreseeable future. The Company has incurred losses from inception of \$16,958 is currently in the development stage and has not commenced commercial operations. The Company’s ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. As at September 30, 2020, the Company had not yet achieved profitable operations and expects to incur further losses in the development of its products, all of which may cast significant doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company not be able to continue as a going concern.

These condensed consolidated interim financial statements were authorized for issue by the Board of Directors on November 26, 2020.

2. **BASIS OF PREPARATION**

Statement of Compliance

These condensed consolidated interim financial statements, including comparatives, have been prepared in accordance with International Accounting Standards (“IAS”) 34, “Interim Financial Reporting” using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and Interpretations issued by the International Financial Reporting Interpretations Committee (“IFRIC”).

These condensed consolidated interim financial statements should be read in conjunction with the Company’s annual financial statements for the year ending December 31, 2019. Certain disclosures that are required to be included in annual financial statements prepared in accordance with IFRS are not included in these condensed consolidated interim financial statements.

Basis of Presentation

The financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value. All dollar amounts presented are in Canadian dollars unless otherwise specified.

2. BASIS OF PREPARATION (CONTINUED)

Basis of Consolidation

These consolidated financial statements include the accounts of Vaxil and its two wholly-owned subsidiaries: (i) Vaxil Israel, which owns 100% of Vaxil Biotherapeutics Ltd. The financial statements of Vaxil are included in the consolidated financial statements from the date that control commences until the date control ceases. Control exists when the Company has the power directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities.

All inter-company balances, and transactions, have been eliminated upon consolidation.

Significant Accounting Judgments and Estimates

The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. The consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and also in future periods when the revision affects both current and future periods.

The critical judgments and significant estimates in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements are:

- The series of loans made to the subsidiary company are considered part of the parent Company's net investment in a foreign operation as the Company does not plan to settle these balances in the foreseeable future. As a result of this assessment, the unrealized foreign exchange gains and losses on the intercompany loans are recorded through other comprehensive loss. If the Company determined that settlement of these amounts was planned or likely in the foreseeable future, the resultant foreign exchange gains and losses would be recorded through profit or loss.
- The change in the fair value of the unsecured convertible loan is based on an estimate determined by the Black-Scholes Model.

Standards issued but not yet effective

Certain pronouncements were issued by the IASB or the IFRIC that are mandatory for future accounting periods. Many are not applicable to or do not have a significant impact on the Company and have been excluded from the list below. The following have not yet been adopted and are being evaluated to determine their impact on Vaxil.

IFRS 17 – Insurance Contract (“IFRS 17”)

IFRS 17 was issued by the IASB in May 2017, which replaces IFRS 4 Insurance Contracts. IFRS 17 requires entities to measure insurance contract liabilities at their current fulfillment values using one of three measurement models, depending on the nature of the contract. IFRS 17 is effective for annual periods beginning on or after January 1, 2021. IFRS 17 will affect how the Company's accounts for its insurance contracts and how it reports its financial performance in our consolidated statements of operations. The Company has determined there will not be a significant impact to the consolidated financial statements as a result of the adoption of this standard.

3. UNSECURED CONVERTIBLE LOANS

On February 3, 2020, the Company received \$36 of unsecured convertible loans from third parties ("Convertible Loans").

The Convertible Loans accrue interest at 10% per annum and the principal and interest ("Repayment Amount") will be repayable by February 3, 2021. The Company shall have the right, but not the obligation, in its sole and absolute discretion, to pay and satisfy the Repayment Amount by the issuance of Common Shares. The conversion price of the principal shall be \$0.05. All Interest conversions, if any, shall be compliant with Policy 4.3 of the TSX-V.

On September 14, 2020, the Company converted all of its outstanding Convertible Loans, in the principle amount of \$36 into 720,000 common shares of the Company. Interest amounting to \$2 was converted into 20,086 Common Shares at the market price of the Common Shares, being \$0.11.

4. UNSECURED NON-CONVERTIBLE LOANS – RELATED PARTIES

On March 4, 2020, the Company issued unsecured non-convertible loans to the directors of the Company in the total amount of \$95 ("Non-Convertible Loans"). The Non-Convertible Loans bear interest at 10% annually and are repayable on or before March 15, 2022. See note 11(ii) for repayment of the Non-Convertible Loans subsequent to the balance sheet date.

5. RELATED PARTY TRANSACTIONS

The following are the compensation paid to key management for the nine months ended September 30, 2020 and 2019 and the balances owing as of September 30, 2020 and 2019:

(i) Nine months ended September 30, 2020:

	Directors Fees	Consulting Fees / Salaries	Share based awards	Total	Amounts owing at September 30, 2020
David Goren, Director and CEO	\$ -	\$ 77	\$ 104	\$ 181	\$ 9
Gadi Levin, Director and CFO	-	45	\$ 43	88	-
Ari Kellen, Director	-	-	-	-	-
Shawn Langer, Director	-	-	-	-	-
Total	\$ -	\$ 122	\$ 147	\$ 269	\$ 9

(i) Nine months ended September 30, 2019:

	Directors Fees	Consulting Fees / Salaries	Share based awards	Total	Amounts owing at December 31, 2019
David Goren, Director and CEO	\$ -	\$ 77	\$ 49	\$ 125	\$ 9
Gadi Levin, Director and CFO	-	45	-	45	10
Ari Kellen, Director	-	-	-	-	-
Shawn Langer, Director	-	-	-	-	-
Total	\$ -	\$ 122	\$ 49	\$ 170	\$ 19

6. SHARE CAPITAL AND RESERVES

a) Authorized share capital

The Company has an unlimited number of common shares without par value. All issued shares, consisting only of common shares are fully paid.

b) During the nine months ended September 30, 2020, \$1,478,000 was received from the exercise of 14,780,000 warrants, having an exercise price of \$0.10 per warrant, that were previously issued in January 2018. Upon exercise of the warrants an additional 14,780,000 common shares of the Company were issued.

c) On September 14, 2020, the Company converted all of its outstanding Convertible Loans and accrued interest into 740,086 shares. See also Note 3.

d) Stock options

(i) Stock option transactions during the year ended December 31, 2019 and the nine months ended September 30, 2020 are summarized as follows:

	Options Issued	Average Exercise Price
Balance January 1, 2019	5,647,684	\$ 0.10
Cancelled	(225,000)	0.10
Balance outstanding at December 31, 2019	5,422,684	\$ 0.10
Cancelled (I)	(390,485)	0.13
Issued (II)	200,000	0.12
Issued (III)	1,400,000	0.12
Balance outstanding at September 30, 2020	6,632,199	\$ 0.10

(I) During the nine month period ended September 30, 2020, 390,485 options with a fair value of \$46 expired.

6. SHARE CAPITAL AND RESERVES (CONTINUED)

d) Stock options (continued)

(II) On September 14, 2020, the Company granted 200,000 stock options (the “Consultant Options”) to two consultants, issued pursuant to the Company's stock option plan (the "SOP"), exercisable into an equal amount of shares at an exercise price of \$0.12 per Share (the "Consultant Options"). 100,000 of the Consultant Options shall vest in three equal installments with 1/3 vesting on the Effective Date (the “Initial Grant”), 1/3 on the 6 month anniversary of the Initial Grant and the last 1/3 on the 12 month anniversary of the Initial Grant. The remaining 100,000 options shall vest in three equal installments with 1/3 vesting on the one-year anniversary of the Initial Grant, 1/3 on the 2 year anniversary of the Initial Grant and the last 1/3 on the 3 year anniversary of the Initial Grant. All Consultant Options shall expire on the 5th anniversary of the Initial Grant.

The Company also granted 1.4 million stock options in aggregate to the CEO and CFO, pursuant to the terms of the SOP, exercisable into an equal amount of share at an exercise price of CAD \$0.12 per Common Share (the "Management Options"). One third of the Management Options vest immediately (the "Initial Date"), one-third vest on the one-year anniversary of the Initial Date, and the remaining amount on the second anniversary of the Initial Date. The Management Options expire 5 years from the Initial Date.

The fair value of the 1,600,000 stock options issued is \$171. \$61 was charged in 2018 to contributed surplus on the consolidated statement of changes in shareholders’ equity (deficiency) representing the vested portion of the expense and was determined using the Black-Scholes option pricing model and the following assumptions: share price - \$0.11; exercise price - \$0.12; expected life – 5 years; annualized volatility – 153%; dividend yield – 0%; risk free rate – 0.48%.

(ii) During the three and nine months ended September 30,2020, the Company charged \$73 and \$108 as share based compensation, respectively (three and nine months ended September 30, 2019: \$31 and \$118, respectively).

(iii) As at September 30, 2020, the Company had outstanding stock options, enabling the holders to acquire further common shares as follows

Options Outstanding			Options Exercisable	
Number Outstanding at September 30, 2020	Exercise Price	Expiry Date	Exercisable at September 30, 2020	Weighted Exercise Price
585,727	\$ 0.125	January 3, 2022	585,727	\$ 0.125
4,446,472	\$ 0.090	September 3, 2023	2,964,315	\$ 0.090
1,600,000	\$ 0.120	September 14, 2025	500,000	\$ 0.120
6,632,199	\$ 0.10		4,050,042	\$ 0.10

6. SHARE CAPITAL AND RESERVES (CONTINUED)

e) Warrants

- (i) Warrant transactions during the year ended December 31, 2019 and nine months ended September 30, 2020 are summarized as follows:

	Warrants Issued	Weighted average exercise price
Balance, January 1, 2019	49,612,501	\$ 0.10
Expired	(12,331,652)	0.36
Balance at December 31, 2019	37,280,849	\$ 0.09
Expired (I)	(1,080,849)	0.36
Exercised (Note 6(b))	(14,780,000)	0.10
Balance at September 30, 2020	21,420,000	\$ 0.10

- (I) During the nine months ended September 30, 2020, 1,080,849 warrants expired with a fair value of \$66 and the Company recorded a charge to the warrant reserve with a corresponding credit to contributed surplus.
- (ii) As at September 30, 2020, the Company had outstanding warrants, enabling the holders to acquire further common shares as follows:

Number of warrants outstanding as of September 30, 2020	Date of expiry	Exercise price
21,420,000	January 26, 2021	\$ 0.10
21,420,000		

7. RESEARCH AND DEVELOPMENT COSTS

	Three months ended Sept 30		Nine Month ended Sept 30	
	2020	2019	2020	2019
	Unaudited		Unaudited	
Wages, salaries and related expenses	\$ 31	\$ 54	\$ 133	\$ 171
Consultants, management and sub-contractors	44	33	50	101
Development materials	20	13	106	100
Patent registrations	28	-	57	-
Depreciation	10	13	39	37
	\$ 133	\$ 113	\$ 385	\$ 409

8. GENERAL AND ADMINISTRATION COSTS

	Three months ended		Nine Month ended	
	September 30		September 30	
	2020	2019	2020	2019
	Unaudited		Unaudited	
Consulting and management fees	\$ 21	\$ 34	63	\$ 62
Professional fees	59	13	163	46
Office rental and other related expenses	14	5	39	9
Depreciation	3	0	7	4
Other	3	11	3	11
	<u>\$ 100</u>	<u>\$ 63</u>	<u>\$ 275</u>	<u>\$ 133</u>

9. COMMITMENTS

- a) The Company has an agreement for the lease of the offices in Israel for a period ending in February 2021, which can be terminated by giving three months' notice. The total future minimum lease payments for three months under the operating lease is \$14.
- b) Since, July 20, 2020, the Company is in an ongoing mediation process with a former officer of the Company in connection with a disagreement regarding compensation.

10. FINANCIAL AND CAPITAL RISK MANAGEMENT

The Company is exposed to varying degrees to a variety of financial instrument related risks:

Fair value

The carrying value of due to/from related parties and accounts payable approximated their fair value because of the relatively short-term nature of these instruments. Cash, which is classified as held for trading and carried at fair value, has been determined using Level 1 inputs.

Foreign exchange risk

The Company's functional and reporting currency is the Canadian dollar and major purchases are transacted in Canadian dollars. As a result, the Company's exposure to foreign currency risk is minimal.

Credit risk

The Company's cash is largely held in large Canadian financial institutions. The Company does not have any asset-backed commercial paper. The Company maintains cash deposits with Schedule A financial institution, which from time to time may exceed federally insured limits. The Company has not experienced any significant credit losses and believes it is not exposed to any significant credit risk.

Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Financial assets and liabilities with variable interest rates expose the Company to cash flow interest rate risk. The Company does not hold any financial liabilities with variable interest rates. The Company does maintain bank accounts which earn interest at variable rates but it does not believe it is currently subject to any significant interest rate risk.

10. FINANCIAL AND CAPITAL RISK MANAGEMENT (CONTINUED)

Liquidity risk

The Company's ability to continue as a going concern is dependent on management's ability to raise required funding through future equity issuances and through short-term borrowing. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of significant expenditures and commitments.

Capital management

The Company defines its capital as shareholders' equity. The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the acquisition and exploration and development of mineral properties. The Board of Directors do not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. As such, the Company has historically relied on the equity markets to fund its activities. In addition, the Company is dependent upon external financings to fund activities. In order to carry out planned exploration and pay for administrative costs, the Company will need to raise additional funds. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

COVID-19

Since January 2020, the Coronavirus outbreak has dramatically expanded into a worldwide pandemic creating macro-economic uncertainty and disruption in the business and financial markets. Many countries around the world, including Canada and the United States have been taking measures designated to limit the continued spread of the Coronavirus, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining populated areas. Such measures present concerns that may dramatically affect the Company's ability to conduct its business effectively, including, but not limited to, adverse effect relating to employees' welfare, slowdown and stoppage of manufacturing, commerce, shipping, delivery, work, travel and other activities which are essential and critical for maintaining on-going business activities. Given the uncertainty around the extent and timing of the future spread or mitigation of COVID-19 and around the imposition or relaxation of protective measures, the Company cannot reasonably estimate the impact to its future results of operations, cash flows or financial condition; infections may become more widespread and the limitation on the ability to work, travel and timely sell and distribute products, as well as any closures or supply disruptions, may be extended for longer periods of time and to other locations, all of which would have a negative impact on the Company's business, financial condition and operating results. In addition, the unknown scale and duration of these developments have macro and micro negative effects on the financial markets and global economy which could result in an economic downturn that could affect demand for the Company's products and have a material adverse effect on its operations and financial results, earnings, cash flow and financial condition.

11. SUBSEQUENT EVENTS

- (i) Subsequent to the balance sheet date, \$35 were received from the exercise of 350,000 warrants, having an exercise price of \$0.10 per warrant, that were previously issued in January 2018. Upon exercise of the warrants an additional 350,000 common shares of the Company were issued.
- (ii) On November 23, 2020, all of the unsecured loans from related parties, including accrued interest, were repaid.
- (iii) On November 23, 2020 the Company completed the first tranche of a previously announced non-brokered private placement for gross proceeds of \$542,858 (the "First Tranche Private Placement"). Investors in the First Tranche Private Placement subscribed for 7,238,108 units ("Units").

In accordance with applicable Canadian securities law the securities issued pursuant to the First Tranche Private Placement are subject to a four month and one day hold period expiring March 24, 2021. In connection with the First Tranche Private Placement, Vaxil paid certain finders fees on a portion of funds raised. Aggregate fees of \$30,303 and the issuance of an aggregate 406,653 Finders' Warrants.

Certain officers and/or directors of the Company (the "Related Parties") participated in the First Tranche Private Placement, which participation constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). Such related party transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of securities being issued to the related parties nor the consideration being paid by the related parties exceeded 25% of the Company's market capitalization.

#####